← Eichor
Study identifier: NCT06604689 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Condition: NSCLC (Advanced Non-small Cell Lung Cancer) · Brain Metastasases  ·  Sponsor: Fudan University

PhaseN/A
Planned participants800
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in NSCLC patients with brain metastases by deep learning, as well as common clinicopathological parameters, which are used to construct a multimode model that can accurately predict the treatment efficacy and survival of the third-generation EGFR-TKI treatment, and to use the model to assist in screening high-risk populations suitable for upfront cranial radiotherapy. Participants receiving third-generation EGFR-TKI treatment will be enrolled in our study and we will collect their regular contrast-enhanced chest CT and contrast-enhanced brain MRI for model construction.

This description comes directly from the study's public registry record.

Talk to the study team

zhengfei Zhu  ·  +86-18017312901  ·  fuscczzf@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Cancer centerShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06604689